Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?

References

• Philip T, Guglielmi C, Hagenbeek A, . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, . Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, . Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007;110:29–36.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Abramson JS, Advani RH, . NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010;8:288–334.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Ho AD, Cavallin-Stahl E, . Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008;9:435–444.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, . Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626–633.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, . Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–641.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, . Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Delarue R, Tilly H, Salles G, . R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA study. Blood 2009;114(Suppl. 1): Abstract 406.
   Google Scholar
• Cunningham D, Smith P, Mouncey P, . A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009;27(15 Suppl.): Abstract 8506.
   Google Scholar
• Cunningham D, Smith P, Mouncey P, . R-CHOP14 versus R-CHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol 2011;29(Suppl.): Abstract 8000.
   Google Scholar
• Gisselbrecht C, Fitoussi O, Belhadj K, . Survival impact of rituximab combined to ACVBP (R-ACVBP) in 209 poor risk diffuse large B-cell lymphoma (DLBCL) patients treated with upfront high-dose consolidative autotransplantation (HDC): a GELA phase II study. Blood 2008;112(Suppl. 1): Abstract 771.
   Google Scholar
• Wilson WH, Dunleavy K, Pittaluga S, . Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26:2717–2724.
   PubMed Web of Science ®Google Scholar
• Ganjoo KN, An CS, Robertson MJ, . Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006;47:998–1005.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Kahl BS, Maurer MJ, . A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer 2006;107:2826–2832.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Gisselbrecht C, Haioun C, . Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer 2009;115:4540–4546.
   PubMed Web of Science ®Google Scholar
• Micallef I, Maurer M, Nikcevich D, . Final results of NCCTG N0489: epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. J Clin Oncol 2009;27(15 Suppl.): Abstract 8508.
   Web of Science ®Google Scholar
• Shipp M. Prognostic factors in non-Hodgkin's lymphoma. Curr Opin Oncol 1992;4:856–862.
   PubMedGoogle Scholar
• Sehn LH, Berry B, Chhanabhai M, . The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, . Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373–2380.
   PubMed Web of Science ®Google Scholar
• Huang JZ, Sanger WG, Greiner TC, . The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002;99:2285–2290.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Ninan MJ, Wadhwa PD, Gupta P. Prognostication of diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 2011;52:360–373.
   PubMed Web of Science ®Google Scholar
• Winter JN, Weller EA, Horning SJ, . Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107:4207–4213.
   PubMed Web of Science ®Google Scholar
• Winter JN, Andersen J, Reed JC, . BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study. Blood 1998;91:1391–1398.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Davis RE, Landgren O, . BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we? Blood 2007;109:843–844; discussion 844–845.
   PubMed Web of Science ®Google Scholar
• Wilson KS, Sehn LH, Berry B, . CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma 2007;48:1102–1109.
   PubMed Web of Science ®Google Scholar
• Safar V, Dupuis J, Itti E, . Interim [18F] fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol 2012;30:184–190.
   PubMed Web of Science ®Google Scholar
• Yang DH, Min JJ, Song HC, . Prognostic significance of interim (1)F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer 2011;47:1312–1318.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Schoder H, Teruya-Feldstein J, . Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol 2010;28:1896–1903.
   PubMed Web of Science ®Google Scholar
• Pregno P, Chiappella A, Bello M, . Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 2012;119:2066–2073.
   PubMed Web of Science ®Google Scholar
• Gianni AM, Bregni M, Siena S, . High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290–1297.
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, . Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1994;12:2543–2551.
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, . Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol—a Groupe d’Etude des Lymphomes de l’Adulte study. J Clin Oncol 2000;18:3025–3030.
   PubMed Web of Science ®Google Scholar
• Milpied N, Deconinck E, Gaillard F, . Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287–1295.
   PubMed Web of Science ®Google Scholar
• Fitoussi O, Belhadj K, Mounier N, . Survival impact of rituximab combined with ACVBP and upfront consolidative autotransplantation in high risk diffuse large B-cell lymphoma for GELA. Haematologica 2011;96:1136–1143.
   PubMed Web of Science ®Google Scholar
• Verdonck LF, van Putten WL, Hagenbeek A, . Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995;332:1045–1051.
   PubMed Web of Science ®Google Scholar
• Santini G, Salvagno L, Leoni P, . VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:2796–2802.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Liberati AM, Cabras MG, . High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an “Intergruppo Italiano Linfomi” randomized trial. Haematologica 2005;90:793–801.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Lepage E, Molina T, . Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002;20:2472–2479.
   PubMed Web of Science ®Google Scholar
• Betticher DC, Martinelli G, Radford JA, . Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol 2006;17:1546–1552.
   PubMed Web of Science ®Google Scholar
• Simon R, Norton L. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol 2006;3:406–407.
   PubMedGoogle Scholar
• Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70:163–169.
   PubMedGoogle Scholar
• Strehl J, Mey U, Glasmacher A, . High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica 2003;88:1304–1315.
   PubMed Web of Science ®Google Scholar
• Greb A, Bohlius J, Schiefer D, . High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst Rev 2008;(1):CD004024.
   Google Scholar
• Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Stiff P, Unger J, Cook J, . Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol 2011;29(Suppl.): Abstract 8001.
   Google Scholar
• Le Gouill S, Milpied N, Lamy T, . First-line rituximab ® high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial. J Clin Oncol 2011;29(Suppl.): Abstract 8003.
   Google Scholar
• Schmitz N, Nickelsen M, Ziepert M, . Conventional chemo - immunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL). J Clin Oncol 2011;29(Suppl.): Abstract 8002.
   Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Juweid ME, Schoder H, . Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 2010;115:775–777; quiz 918.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, . Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184–4190.
   PubMed Web of Science ®Google Scholar
• Martin A, Conde E, Arnan M, . R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008;93:1829–1836.
   PubMed Web of Science ®Google Scholar
• Vose JM, Bierman PJ, Enke C, . Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005;23:461–467.
   PubMed Web of Science ®Google Scholar
• Winter JN, Inwards DJ, Spies S, . Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009;27:1653–1659.
   PubMed Web of Science ®Google Scholar
• Morrison V, Hong F, Habermann T, . R-CHOP versus (vs) CHOP followed by maintenance rituximab (MR) vs observation in older diffuse large B-cell lymphoma (DLBCL) patients (pts): long-term follow-up of intergroup E4494/C9793. Blood 2010;116(Suppl. 1): Abstract 589.
   Google Scholar
• Martelli M, Gherlinzoni F, De Renzo A, . Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol 2003;21: 1255–1262.
   PubMed Web of Science ®Google Scholar
• Kaiser U, Uebelacker I, Abel U, . Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. J Clin Oncol 2002;20:4413–4419.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, . Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 2001;93:22–30.
   PubMed Web of Science ®Google Scholar